Zacks Investment Research downgraded shares of KemPharm (NASDAQ:KMPH) from a buy rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Other equities research analysts have also recently issued research reports about the company. Oppenheimer set a $13.00 price objective on KemPharm and gave the stock a buy rating in a report on Thursday, August 9th. Canaccord Genuity restated a buy rating and set a $11.00 price objective on shares of KemPharm in a report on Tuesday, August 14th. CIBC restated an outperform rating on shares of KemPharm in a report on Friday, September 21st. Finally, ValuEngine upgraded KemPharm from a hold rating to a buy rating in a report on Thursday, August 2nd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $10.33.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.17). Equities analysts predict that KemPharm will post -3.19 earnings per share for the current year.
In other news, major shareholder Delaware Street Capital Master bought 2,000,000 shares of KemPharm stock in a transaction that occurred on Friday, October 5th. The shares were purchased at an average price of $3.00 per share, for a total transaction of $6,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 2,012,650 shares of company stock worth $6,032,461 in the last 90 days. Insiders own 25.90% of the company’s stock.
A number of institutional investors have recently modified their holdings of KMPH. Cowen Inc. acquired a new position in KemPharm in the second quarter valued at $2,381,000. Millennium Management LLC boosted its holdings in KemPharm by 878.0% in the second quarter. Millennium Management LLC now owns 151,250 shares of the specialty pharmaceutical company’s stock valued at $983,000 after acquiring an additional 135,784 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in KemPharm by 101.1% in the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after acquiring an additional 91,400 shares during the last quarter. Bridgeway Capital Management Inc. acquired a new position in KemPharm in the third quarter valued at $264,000. Finally, Vanguard Group Inc. boosted its holdings in KemPharm by 9.3% in the third quarter. Vanguard Group Inc. now owns 479,335 shares of the specialty pharmaceutical company’s stock valued at $2,301,000 after acquiring an additional 40,700 shares during the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Recommended Story: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.